Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

Oncologist

Volumn 11, Issue 4, 2006, Pages 318-324

  Montemurro, Filippo ^a   Donadio, Michela ^b   Clavarezza, Matteo ^c   Redana, Stefania ^a   Jacomuzzi, Maria Elena ^d   Valabrega, Giorgio ^a   Danese, Saverio ^e   Vietti Ramus, Guido ^f   Durando, Antonio ^e   Venturini, Marco ^c   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Istituto Nazionale Tumori   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e S ANNA HOSPITAL   (Italy)

^f S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

HER2; Metastatic breast cancer; Survival; Time to progression; Trastuzumab; Tumor progression

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; LETROZOLE; MEGESTROL ACETATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645792831     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-4-318     Document Type: Article

References (24)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
2. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
5. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
6. Pietras RJ, Pegram MD, Finn RS et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-2249.
7. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251.
8. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.
9. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004;5:52-58; discussion 59-62.
10. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120-125.
11. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-1070.
12. Montemurro F, Choa G, Faggiuolo R et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004;66:38-45.
13. Montemurro F, Faggiuolo R, Redana S et al. Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005;23:2866-2868; discussion 2268-2269.
14. Leyland-Jones B, Arnold A, Gelmon K et al. Pharmacologic insights into the future of trastuzumab. Ann Oncol 2001;12(suppl 1):S43-S47.
15. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
16. Kim YS, Konoplev SN, Montemurro F et al. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 2001;7:4008-4012.
17. Papaldo P, Fabi A, Ferretti G et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 2006 Jan 12; [Epub ahead of print].
18. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127.
19. Valabrega G, Montemurro F, Sarotto I et al. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 2005;24:3002-3010.
20. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist 2004;9(suppl 3):10-15.
21. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005;16:909-914.
22. Hortobagyi GN. Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005;23:2868-2869.
23. German Breast Cancer Group. Herceptin TBP. [German]. Available at http://www.germanbreastgroup.de/herceptin/. Accessed November 11, 2005.
24. National Cancer Institute. Phase III Randomized Study of Vinorelbine With or Without Trastuzumab (Herceptin®) in Women With HER2-Positive Progressive Metastatic Breast Cancer. SWOG-S0347, NCT00103233. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=409573&version= HealthProfessional&protocolsearchid=1800206. Accessed November 11, 2005.